TY - JOUR
T1 - Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan
AU - Mehta, Jyotsna
AU - Wang, Hongwei
AU - Fryzek, Jon P.
AU - Iqbal, Sheikh Usman
AU - Mesa, Ruben
N1 - Funding Information:
Th is study was funded by Sanofi.
Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.
AB - Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) may lead to bone marrow fibrosis. Because the disease course of ET and PV are long and the disease course of MF may be fatal, healthcare resource utilization (HRU) associated costs of these neoplasms are especially important to understand. We used a large US health insurance claim database to describe the costs of these diseases. Compared to age-gender matched comparisons without myeloproliferative neoplasms (MPN), all aspects of HRU that we examined, including inpatient, outpatient and emergency room visits and pharmacy, as well as overall healthcare expenditures, were significantly higher in patients with MF, PV and ET (e.g. MF total costs = $54 168 vs. $10 203; PV = $14 903 vs. $7913; ET = $29 553 vs. $8026) than in matched comparisons. In order to reduce the burden of illness associated with these diseases, continued efforts in the development of more efficacious treatments for these disorders are needed.
KW - Health resource utilization
KW - Myeloproliferative disorders
UR - http://www.scopus.com/inward/record.url?scp=84925326065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925326065&partnerID=8YFLogxK
U2 - 10.3109/10428194.2013.879127
DO - 10.3109/10428194.2013.879127
M3 - Article
C2 - 24450579
AN - SCOPUS:84925326065
SN - 1042-8194
VL - 55
SP - 2368
EP - 2374
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -